Title:
HDAC INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY
Document Type and Number:
WIPO Patent Application WO/2019/043176
Kind Code:
A3
Abstract:
The invention relates to methods, compositions and uses for the of treatment of cancer comprising the administration of an HDAC inhibitor for the treatment of cancer in combination with an antimetabolite agent.
Inventors:
SATOMI MASAHIKO (JP)
NAKAMURA OSAMU (JP)
KRAUSS ROLF (DE)
NAKAMURA OSAMU (JP)
KRAUSS ROLF (DE)
Application Number:
PCT/EP2018/073504
Publication Date:
April 11, 2019
Filing Date:
August 31, 2018
Export Citation:
Assignee:
4SC AG (DE)
YAKULT HONSHA KK (JP)
YAKULT HONSHA KK (JP)
International Classes:
A61K45/06; A61K31/4025; A61K31/513; A61P35/00
Other References:
SHUAI GAO ET AL: "Preclinical and Clinical Studies of Chidamide (CS055/HBI-8000), An Orally Available Subtype-selective HDAC Inhibitor for Cancer Therapy", ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, vol. 17, no. 6, 5 June 2017 (2017-06-05), NL, XP055530087, ISSN: 1871-5206, DOI: 10.2174/1871520616666160901150427
ANONYMOUS: "4SC-201 (Resminostat) in Advanced Colorectal Carcinoma", 1 February 2015 (2015-02-01), pages 1 - 8, XP055530023, Retrieved from the Internet [retrieved on 20181204]
NOEMI ARRIGHETTI ET AL: "Drug Combinations with HDAC Inhibitors in Antitumor Therapy", CRITICAL REVIEWS IN ONCOGENESIS, vol. 20, no. 1-2, 1 January 2015 (2015-01-01), pages 83 - 117, XP055369440, ISSN: 0893-9675, DOI: 10.1615/CritRevOncog.2014012378
SHUICHI IWAHASHI ET AL: "Effects of Valproic Acid in Combination with S-1 on Advanced Pancreatobiliary Tract Cancers: Clinical Study Phases I/II", ANTICANCER RESEARCH, vol. 34, no. 9, 1 September 2014 (2014-09-01), pages 5187 - 5192, XP055530060
RINTARO NORO ET AL: "Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21waf1/cip1 expression", CANCER SCIENCE, vol. 101, no. 6, 10 March 2010 (2010-03-10), JP, pages 1424 - 1430, XP055530053, ISSN: 1347-9032, DOI: 10.1111/j.1349-7006.2010.01559.x
ELENA DI GENNARO ET AL: "Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or Raltitrexed", CANCER BIOLOGY & THERAPY, vol. 8, no. 9, 1 May 2009 (2009-05-01), US, pages 782 - 791, XP055530078, ISSN: 1538-4047, DOI: 10.4161/cbt.8.9.8118
CHIGUZA MORIZANE ET AL: "Phase I study of resminostat, an HDAC inhibitor, combined with S-1 in patients with pre-treated biliary tract or pancreatic cancer", INVESTIGATIONAL NEW DRUGS., vol. 28, no. Suppl. 5, 1 September 2017 (2017-09-01), US, pages 1 - 9, XP055530038, ISSN: 0167-6997, DOI: 10.1093/annonc/mdx369.130
ANONYMOUS: "4SC-201 (Resminostat) in Advanced Colorectal Carcinoma", 1 February 2015 (2015-02-01), pages 1 - 8, XP055530023, Retrieved from the Internet
NOEMI ARRIGHETTI ET AL: "Drug Combinations with HDAC Inhibitors in Antitumor Therapy", CRITICAL REVIEWS IN ONCOGENESIS, vol. 20, no. 1-2, 1 January 2015 (2015-01-01), pages 83 - 117, XP055369440, ISSN: 0893-9675, DOI: 10.1615/CritRevOncog.2014012378
SHUICHI IWAHASHI ET AL: "Effects of Valproic Acid in Combination with S-1 on Advanced Pancreatobiliary Tract Cancers: Clinical Study Phases I/II", ANTICANCER RESEARCH, vol. 34, no. 9, 1 September 2014 (2014-09-01), pages 5187 - 5192, XP055530060
RINTARO NORO ET AL: "Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21waf1/cip1 expression", CANCER SCIENCE, vol. 101, no. 6, 10 March 2010 (2010-03-10), JP, pages 1424 - 1430, XP055530053, ISSN: 1347-9032, DOI: 10.1111/j.1349-7006.2010.01559.x
ELENA DI GENNARO ET AL: "Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or Raltitrexed", CANCER BIOLOGY & THERAPY, vol. 8, no. 9, 1 May 2009 (2009-05-01), US, pages 782 - 791, XP055530078, ISSN: 1538-4047, DOI: 10.4161/cbt.8.9.8118
CHIGUZA MORIZANE ET AL: "Phase I study of resminostat, an HDAC inhibitor, combined with S-1 in patients with pre-treated biliary tract or pancreatic cancer", INVESTIGATIONAL NEW DRUGS., vol. 28, no. Suppl. 5, 1 September 2017 (2017-09-01), US, pages 1 - 9, XP055530038, ISSN: 0167-6997, DOI: 10.1093/annonc/mdx369.130
Attorney, Agent or Firm:
BOEHMERT & BOEHMERT (DE)
Download PDF:
Previous Patent: BODY PART HAVING A METALLIZED SURFACE FORMING A WHEEL COVER AND LIGHT REFLECTOR
Next Patent: SPIROTHIETANE NUCLEOSIDES
Next Patent: SPIROTHIETANE NUCLEOSIDES